Tags: Genetics
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
blog
September 24, 2018
Two Decades of Research: The ADDF’s 19th International Conference on Alzheimer’s Drug Discovery
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
announcements
September 21, 2018
19th International Conference on Alzheimer’s Drug Discovery Highlights Multiple Approaches
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
blog
June 20, 2018
Gene Therapy, A New Frontier in Alzheimer’s
Dr. Ron Crystal and his team at Weill Cornell developed a gene therapy to replace APOE4 with APOE2, which would significantly lower Alzheimer's risk.
blog
June 14, 2018
Familial Alzheimer’s Disease, Explained
Learn about early-onset familial Alzheimer's disease, which can strike people as early as their 30s or 40s.
blog
August 18, 2014
Drugs to “Fix” the APOE4 Gene May Be Safe
New research reveals that a person without the APOE gene—which influences Alzheimer’s risk—can function normally, paving the way for gene therapies.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).